IN2013MU03596A - - Google Patents
Download PDFInfo
- Publication number
- IN2013MU03596A IN2013MU03596A IN3596MU2013A IN2013MU03596A IN 2013MU03596 A IN2013MU03596 A IN 2013MU03596A IN 3596MU2013 A IN3596MU2013 A IN 3596MU2013A IN 2013MU03596 A IN2013MU03596 A IN 2013MU03596A
- Authority
- IN
- India
- Prior art keywords
- solvent
- dehalogenated
- formation
- minimising
- present
- Prior art date
Links
- 230000015572 biosynthetic process Effects 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 239000002904 solvent Substances 0.000 abstract 3
- AHOUBRCZNHFOSL-UHFFFAOYSA-N 3-(1,3-benzodioxol-5-yloxymethyl)-4-(4-fluorophenyl)piperidine Chemical compound C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 abstract 2
- 239000006227 byproduct Substances 0.000 abstract 2
- 239000012280 lithium aluminium hydride Substances 0.000 abstract 2
- VSWBSWWIRNCQIJ-GJZGRUSLSA-N (R,R)-asenapine Chemical compound O1C2=CC=CC=C2[C@@H]2CN(C)C[C@H]2C2=CC(Cl)=CC=C21 VSWBSWWIRNCQIJ-GJZGRUSLSA-N 0.000 abstract 1
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 1
- 229960005245 asenapine Drugs 0.000 abstract 1
- 239000003638 chemical reducing agent Substances 0.000 abstract 1
- VDHAWDNDOKGFTD-MRXNPFEDSA-N cinacalcet Chemical compound N([C@H](C)C=1C2=CC=CC=C2C=CC=1)CCCC1=CC=CC(C(F)(F)F)=C1 VDHAWDNDOKGFTD-MRXNPFEDSA-N 0.000 abstract 1
- 229960003315 cinacalcet Drugs 0.000 abstract 1
- 239000006184 cosolvent Substances 0.000 abstract 1
- OTLDLQZJRFYOJR-LJQANCHMSA-N eletriptan Chemical compound CN1CCC[C@@H]1CC1=CN=C2[C]1C=C(CCS(=O)(=O)C=1C=CC=CC=1)C=C2 OTLDLQZJRFYOJR-LJQANCHMSA-N 0.000 abstract 1
- 229960002472 eletriptan Drugs 0.000 abstract 1
- 150000002894 organic compounds Chemical class 0.000 abstract 1
- 229960005183 paroxetine hydrochloride Drugs 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/86—Oxygen atoms
- C07D211/88—Oxygen atoms attached in positions 2 and 6, e.g. glutarimide
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN3596MU2013 IN2013MU03596A (ja) | 2013-11-18 | 2014-11-12 | |
| PCT/IB2014/065978 WO2015071831A1 (en) | 2013-11-18 | 2014-11-12 | An improved process for minimising the formation of dehalogenated byproducts |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN3596MU2013 IN2013MU03596A (ja) | 2013-11-18 | 2014-11-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2013MU03596A true IN2013MU03596A (ja) | 2015-07-24 |
Family
ID=53056868
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN3596MU2013 IN2013MU03596A (ja) | 2013-11-18 | 2014-11-12 |
Country Status (2)
| Country | Link |
|---|---|
| IN (1) | IN2013MU03596A (ja) |
| WO (1) | WO2015071831A1 (ja) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115813888A (zh) | 2016-12-20 | 2023-03-21 | 罗曼治疗系统股份公司 | 包含阿塞那平的透皮治疗系统 |
| EP3558276B1 (en) | 2016-12-20 | 2024-11-06 | LTS Lohmann Therapie-Systeme AG | Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene |
| WO2019002204A1 (en) | 2017-06-26 | 2019-01-03 | Lts Lohmann Therapie-Systeme Ag | TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING ASENAPINE AND SILICONE-TYPE ACRYLIC HYBRID POLYMER |
| US12329862B2 (en) | 2018-06-20 | 2025-06-17 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine |
| AU2019291060B2 (en) | 2018-06-20 | 2024-09-05 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0223334B1 (en) * | 1985-08-10 | 1991-07-10 | Beecham Group Plc | Process for the preparation of aryl-piperidine carbinols |
| CN1068597C (zh) * | 1995-05-17 | 2001-07-18 | 诺沃挪第克公司 | 制备4－芳基－哌啶衍生物的方法 |
| US6444190B2 (en) * | 1995-08-03 | 2002-09-03 | Fmc Corporation | Reduction compositions and processes for making the same |
| JP3446468B2 (ja) * | 1996-04-15 | 2003-09-16 | 旭硝子株式会社 | ピペリジンカルビノール類の製造方法 |
| WO2008058235A2 (en) * | 2006-11-08 | 2008-05-15 | Dr. Reddy's Laboratories, Ltd. | Processes for the preparation of cinacalcet |
-
2014
- 2014-11-12 WO PCT/IB2014/065978 patent/WO2015071831A1/en not_active Ceased
- 2014-11-12 IN IN3596MU2013 patent/IN2013MU03596A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015071831A1 (en) | 2015-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014KN00948A (ja) | ||
| MX2020000268A (es) | Agonista de fxr. | |
| MX2009008541A (es) | Fenilcarbamatos macrociclicos que inhiben el virus de hepatitis c. | |
| MX2009008540A (es) | Inhibidores de virus de hepatitis c macrociclicos sustituidos con pirimidina. | |
| WO2016044641A3 (en) | Carm1 inhibitors and uses thereof | |
| MX363127B (es) | Derivados de benzotiofeno como inhibidores del receptor de estrogeno. | |
| EP4643945A3 (en) | Neuroactive steroids and methods of use thereof | |
| IN2013MU03596A (ja) | ||
| MX2015008975A (es) | Analogos de tiadiazol y metodos para el tratamiento de afecciones relacionadas con deficiencia del gen de supervivencia de las neuronas motoras (smn). | |
| JO3494B1 (ar) | مشتقات بنزوثيوفين وتركيبات منها كمواد انحلال لمستقبلات استروجين انتقائية | |
| EP4219465A3 (en) | Prmt5 inhibitors and uses thereof | |
| PH12014500200A1 (en) | Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as c5a receptor modulators | |
| MX2015005858A (es) | Moduladores del receptor acoplado a proteina g (gpr40) de dihidropirazol. | |
| TN2016000556A1 (en) | Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators | |
| PH12016502034B1 (en) | Pyrrolidine gpr40 modulators for the treatment of diseases such as diabetes | |
| JOP20180071A1 (ar) | استخدام مشتقات أمينو ألكيل بنزوثيازبين | |
| CL2017001479A1 (es) | Combinación farmacéutica que comprende un agonista selectivo del receptor s1p1 | |
| TW200806291A (en) | Pharmaceutical formulations | |
| PH12016502246B1 (en) | Carboxamide derivatives | |
| MX362919B (es) | Moduladores del receptor acoplado a proteína-g 120 (gpr120) de ácido biciclo-[2.2.1]. | |
| SG194696A1 (en) | Isoxazolines as therapeutic agents | |
| MX2016014946A (es) | Derivados de carboxamida. | |
| MX394860B (es) | Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk). | |
| MX2017008074A (es) | DERIVADOS DE IMIDAZOPIRIDAZINA COMO INHIBIDORES DE FOSFOINOSITIDA-3-QUINASAS BETA (PI3Kß). | |
| MX2016014118A (es) | Moduladores de receptor de proteina g 40 (gpr40) de pirrolidina para tratamiento de enfermedades tales como diabetes. |